PL364348A1 - Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego - Google Patents

Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego

Info

Publication number
PL364348A1
PL364348A1 PL04364348A PL36434804A PL364348A1 PL 364348 A1 PL364348 A1 PL 364348A1 PL 04364348 A PL04364348 A PL 04364348A PL 36434804 A PL36434804 A PL 36434804A PL 364348 A1 PL364348 A1 PL 364348A1
Authority
PL
Poland
Prior art keywords
application
protection agent
pyridine salts
vessel protection
quaternary pyridine
Prior art date
Application number
PL04364348A
Other languages
English (en)
Inventor
Jerzy Gębicki
Stefan Chłopicki
Original Assignee
PHARMENA Sp.z o.o.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by PHARMENA Sp.z o.o. filed Critical PHARMENA Sp.z o.o.
Priority to PL04364348A priority Critical patent/PL364348A1/pl
Priority to EP05726215A priority patent/EP1713480B1/en
Priority to ES05726215T priority patent/ES2372756T3/es
Priority to AT05726215T priority patent/ATE524179T1/de
Priority to US10/585,892 priority patent/US7935717B2/en
Priority to PL05726215T priority patent/PL1713480T3/pl
Priority to RU2006129299/15A priority patent/RU2366420C2/ru
Priority to AU2005205066A priority patent/AU2005205066C1/en
Priority to EP10180501A priority patent/EP2279738A1/en
Priority to JP2006548308A priority patent/JP5052138B2/ja
Priority to CA2547234A priority patent/CA2547234C/en
Priority to CN2005800017124A priority patent/CN1905875B/zh
Priority to DK05726215.6T priority patent/DK1713480T3/da
Priority to PCT/EP2005/050057 priority patent/WO2005067927A2/en
Priority to PT05726215T priority patent/PT1713480E/pt
Publication of PL364348A1 publication Critical patent/PL364348A1/pl
Priority to US12/685,377 priority patent/US8124631B2/en
Priority to US13/083,106 priority patent/US8969391B2/en
Priority to JP2011233155A priority patent/JP5597179B2/ja
Priority to US14/303,054 priority patent/US9119844B2/en
Priority to US14/598,888 priority patent/US9333196B2/en
Priority to US15/146,485 priority patent/US9675601B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Physiology (AREA)
  • Psychology (AREA)
  • Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
PL04364348A 2004-01-12 2004-01-12 Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego PL364348A1 (pl)

Priority Applications (21)

Application Number Priority Date Filing Date Title
PL04364348A PL364348A1 (pl) 2004-01-12 2004-01-12 Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego
JP2006548308A JP5052138B2 (ja) 2004-01-12 2005-01-07 四級ピリジニウム塩の血管保護剤としての使用
DK05726215.6T DK1713480T3 (da) 2004-01-12 2005-01-07 Anvendelse af kvaternære pyridiniumsalte som vasobeskyttende midler
AT05726215T ATE524179T1 (de) 2004-01-12 2005-01-07 Verwendung von quartären pyridiniumsalzen als gefässschutzmittel
US10/585,892 US7935717B2 (en) 2004-01-12 2005-01-07 Method for treating hypertriglyceridemia, dyslipidemia and hypercholesterolemia with a 1-methylnicotinamide salt
PL05726215T PL1713480T3 (pl) 2004-01-12 2005-01-07 Zastosowanie czwartorzędowych soli pirydyniowych jako środków naczynioprotekcyjnych
RU2006129299/15A RU2366420C2 (ru) 2004-01-12 2005-01-07 Применение четвертичных солей пиридиния в качестве вазопротекторных средств
AU2005205066A AU2005205066C1 (en) 2004-01-12 2005-01-07 The use of quaternary pyridinium salts as vasoprotective agents
EP10180501A EP2279738A1 (en) 2004-01-12 2005-01-07 The use of quaternary pyridinium salts as vasoprotective agents
EP05726215A EP1713480B1 (en) 2004-01-12 2005-01-07 The use of quaternary pyridinium salts as vasoprotective agents
CA2547234A CA2547234C (en) 2004-01-12 2005-01-07 The use of quaternary pyridinium salts as vasoprotective agents
CN2005800017124A CN1905875B (zh) 2004-01-12 2005-01-07 吡啶*盐作为血管保护剂的用途
ES05726215T ES2372756T3 (es) 2004-01-12 2005-01-07 Uso de sales de piridinio cuaternario como agentes vasoprotectores.
PCT/EP2005/050057 WO2005067927A2 (en) 2004-01-12 2005-01-07 The use of quaternary pyridinium salts as vasoprotective agents
PT05726215T PT1713480E (pt) 2004-01-12 2005-01-07 Utilização de sais quaternários de piridínio como agentes vasoprotectores
US12/685,377 US8124631B2 (en) 2004-01-12 2010-01-11 Use of quaternary pyridinium salts as vasoprotective agents
US13/083,106 US8969391B2 (en) 2004-01-12 2011-04-08 Use quaternary pyridinium salts as vasoprotective agents
JP2011233155A JP5597179B2 (ja) 2004-01-12 2011-10-24 四級ピリジニウム塩の血管保護剤としての使用
US14/303,054 US9119844B2 (en) 2004-01-12 2014-06-12 Use of quaternary pyridinium salts as vasoprotective agents
US14/598,888 US9333196B2 (en) 2004-01-12 2015-01-16 Use of quaternary pyridinium salts as vasoprotective agents
US15/146,485 US9675601B2 (en) 2004-01-12 2016-05-04 Use of quaternary pyridinium salts as vasoprotective agents

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL04364348A PL364348A1 (pl) 2004-01-12 2004-01-12 Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego

Publications (1)

Publication Number Publication Date
PL364348A1 true PL364348A1 (pl) 2005-07-25

Family

ID=34793495

Family Applications (2)

Application Number Title Priority Date Filing Date
PL04364348A PL364348A1 (pl) 2004-01-12 2004-01-12 Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego
PL05726215T PL1713480T3 (pl) 2004-01-12 2005-01-07 Zastosowanie czwartorzędowych soli pirydyniowych jako środków naczynioprotekcyjnych

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL05726215T PL1713480T3 (pl) 2004-01-12 2005-01-07 Zastosowanie czwartorzędowych soli pirydyniowych jako środków naczynioprotekcyjnych

Country Status (13)

Country Link
US (6) US7935717B2 (pl)
EP (2) EP1713480B1 (pl)
JP (2) JP5052138B2 (pl)
CN (1) CN1905875B (pl)
AT (1) ATE524179T1 (pl)
AU (1) AU2005205066C1 (pl)
CA (1) CA2547234C (pl)
DK (1) DK1713480T3 (pl)
ES (1) ES2372756T3 (pl)
PL (2) PL364348A1 (pl)
PT (1) PT1713480E (pl)
RU (1) RU2366420C2 (pl)
WO (1) WO2005067927A2 (pl)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014200373A1 (en) * 2013-06-11 2014-12-18 Uniwersytet Jagielloński 3-carbamoyl-1 -methylpyridinium nitrite, process for its preparation and its use

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL364348A1 (pl) 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego
WO2007074406A2 (en) 2005-07-11 2007-07-05 Pharmena North America Inc. Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
ATE438625T1 (de) * 2005-12-09 2009-08-15 Cerecon Ag Quaternäre 3-amido, n-methylpyridiniumsalze als entzündungshemmende mittel
DK2026651T3 (da) 2006-03-08 2013-07-08 Cortria Corp Kombinationsterapi med ikke-selektive COX-inhibitorer til forebyggelse af COX-relaterede maveskader
CA2700585A1 (en) * 2006-10-18 2008-08-14 Dermena North America, Inc. Food extracts for treatment of lipoprotein abnormalities and skin diseases and skin disorders
PL381862A1 (pl) 2007-02-28 2008-09-01 Trigendo Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie związków pirydyniowych i sposób leczenia
WO2009042440A1 (en) * 2007-09-28 2009-04-02 Cortria Corporation 1-methyl nicotinamide and derivatives for treatment of gastric injury
PL2211857T3 (pl) * 2007-10-12 2012-11-30 Politechnika Lodzka Zastosowanie czwartorzędowych soli pirydyniowych do radioprotekcji
PL2211858T3 (pl) 2007-10-12 2015-06-30 Politechnika Lodzka Zastosowanie czwartorzędowych soli pirydyniowych do hamowania przerzutów nowotworowych
US8304439B1 (en) 2007-10-12 2012-11-06 Politechnika Lodzka Use of quaternary pyridinium salts as a therapeutic or preventing agent against ionizing radiation-induced damage
MX2010012106A (es) * 2008-05-06 2011-03-21 Cortria Corp Analogos de 1-metilnicotinamida.
EP2307380B1 (en) * 2008-07-01 2012-10-24 Politechnika Lódzka N'-nitroxyalkylnicotinamides for the treatment of cardiovascular diseases
CA2730599C (en) * 2008-07-23 2016-09-13 Toray Industries, Inc. Therapeutic agent for chronic renal failure
EP2186419A1 (en) * 2008-11-13 2010-05-19 Tchibo GmbH NMP-containing extract, a method of its production and uses thereof
RU2425672C1 (ru) * 2010-04-12 2011-08-10 Государственное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет Федерального агентства по здравоохранению и социальному развитию" Способ коррекции гипергомоцистеин-индуцированной эндотелиальной дисфункции смесью растворов гомеопатических разведений поликлональных кроличьих антител к эндотелиальной синтазе оксида азота человека - с12, с30, с200
KR101309576B1 (ko) * 2011-05-25 2013-09-17 연세대학교 산학협력단 대사물질을 이용한 심부전 바이오마커
CN105771005A (zh) * 2016-03-24 2016-07-20 乐普（北京）医疗器械股份有限公司 一种抗风湿性血管狭窄药物支架及其制备方法和应用
PL3484475T3 (pl) * 2016-07-18 2024-03-11 Pharmena S.A. 1-Metylonikotynamid do leczenia choroby układu krążenia
WO2018015862A1 (en) 2016-07-18 2018-01-25 Pharmena S.A. 1-methylnicotinamide salts for use in raising the blood levels of adiponectin
US11426368B2 (en) * 2017-07-27 2022-08-30 The Regents Of The University Of Michigan Plasminogen activator inhibitor-1 (PAI-1) inhibitor and method of use
PL238932B1 (pl) * 2017-12-31 2021-10-18 Univ Jagiellonski Pochodne soli pirydyniowych oraz ich zastosowanie
US10864207B2 (en) * 2019-01-02 2020-12-15 Celagenex Research (India) Pvt. Ltd. Method of treating endothelial dysfunction
WO2021205341A1 (en) 2020-04-07 2021-10-14 Pharmena S.A. 1-methylnicotinamide for the prevention/treatment of inflammatory airway diseases
US20230330040A1 (en) * 2020-09-21 2023-10-19 The Regents Of The University Of California Immunological effects of metabolites
CN115837023B (zh) * 2023-02-20 2023-05-16 中山大学附属第八医院（深圳福田） 1-甲基烟酰胺在制备抗血管钙化药物中的应用
US20240350475A1 (en) * 2023-04-13 2024-10-24 University Of South Carolina Trigonelline mitigates cardiomyopathy caused by sars-cov-2 spike protein under obesity
PL248942B1 (pl) * 2024-01-31 2026-02-16 Politechnika Poznanska Czwartorzędowe sole amoniowe zawierające anion 2-furanokarboksylanowy i kation będący alkilową pochodną nikotynamidu, sposób ich otrzymywania i zastosowanie jako środki myjąco-dezynfekujące
PL447656A1 (pl) * 2024-01-31 2025-08-04 Politechnika Poznańska Nowe czwartorzędowe sole amoniowe zawierające anion pochodzący od kwasu nikotynowego oraz kation N-alkilonikotynamidowy, sposób ich otrzymywania oraz zastosowanie jako substancje o aktywności przeciwbakteryjnej
PL449092A1 (pl) * 2024-07-01 2026-01-05 Uniwersytet Jagielloński Synergiczna kombinacja 1-metylonikotynamidu (MNA) i witaminy K do zastosowania w leczeniu lub zapobieganiu powikłaniom sercowo-naczyniowym terapii przeciwnowotworowych

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB675430A (en) 1949-07-12 1952-07-09 Cilag Ltd Novel quaternary nicotinic acid amide derivatives and production thereof
DE840698C (de) * 1949-07-12 1952-06-05 Cilag Aktiengesellschaft Verfahren zur herstellung neuer derivate des nicotinsaureamids
US5260305A (en) * 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
US20060263428A1 (en) * 1993-09-20 2006-11-23 Eugenio Cefali Methods for treating hyperlipidemia with intermediate release nicotinic acid compositions having unique biopharmaceutical characteristics
US6746691B2 (en) * 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6818229B1 (en) * 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6406715B1 (en) * 1993-09-20 2002-06-18 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique urinary metabolite profiles
US6676967B1 (en) * 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US20030161880A1 (en) * 1997-03-06 2003-08-28 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
US6469035B1 (en) * 1997-07-31 2002-10-22 Eugenio A. Cefali Methods of pretreating hyperlipidemic individuals with a flush inhibiting agent prior to the start of single daily dose nicotinic acid therapy to reduce flushing provoked by nicotinic acid
IE970731A1 (en) * 1997-10-07 2000-10-04 Fuisz Internat Ltd Product and method for the treatment of hyperlipidemia
PL190755B1 (pl) * 1999-01-07 2006-01-31 Pharmena Sp Z Oo Preparat do leczenia i profilaktyki chorób skóry
JP2002255846A (ja) * 2001-02-26 2002-09-11 Sunstar Inc 経口組成物
US20050130990A1 (en) * 2001-03-23 2005-06-16 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
CA2341952A1 (en) * 2001-03-23 2002-09-23 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
US8039459B2 (en) * 2004-07-15 2011-10-18 Universite Laval Nicotinic receptor agonists for the treatment of inflammatory diseases
US7153870B2 (en) * 2003-07-25 2006-12-26 Pfizer Inc. Nicotinamide derivatives useful as PDE4 inhibitors
PL364348A1 (pl) 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego
JP2008519080A (ja) 2004-11-05 2008-06-05 アリーナ ファーマシューティカルズ， インコーポレイテッド ナイアシン受容体部分的アゴニストを含む、潮紅および脂質関連障害を処置するための組成物
WO2007074406A2 (en) 2005-07-11 2007-07-05 Pharmena North America Inc. Formulations for treatment of lipoprotein abnormalities comprising a statin a statin and a methylnicotinamide derivative
CA2700585A1 (en) * 2006-10-18 2008-08-14 Dermena North America, Inc. Food extracts for treatment of lipoprotein abnormalities and skin diseases and skin disorders
PL381862A1 (pl) * 2007-02-28 2008-09-01 Trigendo Spółka Z Ograniczoną Odpowiedzialnością Zastosowanie związków pirydyniowych i sposób leczenia

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014200373A1 (en) * 2013-06-11 2014-12-18 Uniwersytet Jagielloński 3-carbamoyl-1 -methylpyridinium nitrite, process for its preparation and its use

Also Published As

Publication number Publication date
US9333196B2 (en) 2016-05-10
AU2005205066C1 (en) 2010-08-26
US7935717B2 (en) 2011-05-03
US9119844B2 (en) 2015-09-01
CN1905875A (zh) 2007-01-31
DK1713480T3 (da) 2012-01-16
WO2005067927A3 (en) 2005-12-01
ES2372756T3 (es) 2012-01-26
WO2005067927A2 (en) 2005-07-28
JP2007517833A (ja) 2007-07-05
US20080207702A1 (en) 2008-08-28
US8124631B2 (en) 2012-02-28
PT1713480E (pt) 2011-11-28
US20160346265A1 (en) 2016-12-01
AU2005205066B2 (en) 2010-04-29
RU2006129299A (ru) 2008-02-20
CN1905875B (zh) 2010-07-28
RU2366420C2 (ru) 2009-09-10
US20110245297A1 (en) 2011-10-06
US8969391B2 (en) 2015-03-03
CA2547234A1 (en) 2005-07-28
US20150133508A1 (en) 2015-05-14
CA2547234C (en) 2010-07-20
US20100173956A1 (en) 2010-07-08
EP2279738A1 (en) 2011-02-02
ATE524179T1 (de) 2011-09-15
JP5597179B2 (ja) 2014-10-01
EP1713480B1 (en) 2011-09-14
JP5052138B2 (ja) 2012-10-17
PL1713480T3 (pl) 2011-12-30
US20140296305A1 (en) 2014-10-02
AU2005205066A1 (en) 2005-07-28
US9675601B2 (en) 2017-06-13
EP1713480A2 (en) 2006-10-25
JP2012072150A (ja) 2012-04-12

Similar Documents

Publication Publication Date Title
PL1713480T3 (pl) Zastosowanie czwartorzędowych soli pirydyniowych jako środków naczynioprotekcyjnych
MY133732A (en) Sulfonylcarboxamide derivatives, process for their preparation and their use as medicines
SI1487444T1 (sl) Uporaba piridil-amidov kot inhibitorjev angiogeneze
AP2002002637A0 (en) Novel piperazine
TW200728307A (en) Novel spirochromanone derivatives
TW200635582A (en) Medicaments for the treatment or prevention of fibrotic diseases
IL166298A0 (en) 8-hydroxy quinoline derivatives
HU229581B1 (en) Glucopyranosyloxypyrazole derivatives, medicinal compositions containing the same and intermediates in the production thereof
TW200716574A (en) The preparation and use of compounds as aspartyl protease inhibitors
TR200402656T4 (tr) Antikanser ajanları olarak faydalı tiyofen türevleri
TW200420549A (en) Thiazole derivatives
PT1513519E (pt) Uso de cianopirrolidinas substituídas e preparações de combinações que as contêm para tratar hiperlipidemia e doenças associadas
MY129796A (en) Novel anti-inflammatory androstane derivatives
WO2002051832A3 (en) Heterocyclylalkylindole or -azaindole compounds as 5-hydroxytryptamine-6 ligands
WO2007066784A3 (en) Diarylether derivatives as antitumor agents
AP2001002306A0 (en) Bridged piperazine derivatives.
BR0312798A (pt) Derivados de isotiazol úteis como agentes anticancerìgenos
IL177494A0 (en) Use of methylene amide derivatives in cardiovascular disorders
PL1784402T3 (pl) Pochodne pirolo[3,2-c]pirydyny oraz sposoby ich wytwarzania
TW200640462A (en) Compounds
WO2006050861A3 (en) Statine derivatives for the treatment of alzheimer's disease
TW200714593A (en) Agent for treatment of solid tumor
MX2009006634A (es) Compuestos de imidazolidinonil aminopirimidina para el tratamiento de cancer.
CA2374902A1 (en) Aminoalkyl substituted benzopyran derivatives for treating impaired fundic relaxation
WO2006031719A3 (en) 1,4-bis-n-oxide-5,8-dihydroxyanthracenedione compounds and the use thereof

Legal Events

Date Code Title Description
DISC Decisions on discontinuance of the proceedings (taken after the publication of the particulars of the applications)